Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) manufacturer of medicines for serious diseases will be discussing 3Q20 financial results with the investment community.on 29th October 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.vrtx.com
Earnings Expectation
Vertex Pharmaceuticals Incorporated is reporting third quarter financial results on Thursday 29th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, VRTX is expected to report 3Q20 income of $ 2.34 per share from revenue of $ 1484.99 million.
For the full year, analysts anticipate top line of $ 6019.24 million, while looking forward to income of $ 9.84 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 5,700.00 million ~ $ 5,900.00 million
Click Here For More Historical Outlooks Of Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency.
